Peter Kies - 15 May 2025 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role
CFO
Signature
/s/ Peter Kies
Issuer symbol
INO
Transactions as of
15 May 2025
Net transactions value
-$5,004
Form type
4
Filing time
16 May 2025, 16:08:24 UTC
Previous filing
28 Feb 2025
Next filing
21 May 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KIES PETER CFO C/O INOVIO PHARMACEUTICALS, INC., 6769 MESA RIDGE ROAD, SAN DIEGO /s/ Peter Kies 16 May 2025 0001259780

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INO Common Stock Options Exercise +4,771 +17% 32,823 15 May 2025 Direct F1
transaction INO Common Stock Tax liability $5,004 -2,566 -7.8% $1.95 30,257 15 May 2025 Direct F2
holding INO Common Stock 375 15 May 2025 By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Restricted Stock Unit Options Exercise $0 -4,771 -50% $0.000000 4,771 15 May 2025 Common Stock 4,771 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 14,313 restricted stock units is as follows: 4,771 shares vested on May 15, 2024; 4,771 shares vested on May 15, 2025; and 4,771 shares will vest on May 15, 2026. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.